Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1193-1204

  Zhao, Xiaobin B ^a   Lee, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

All trans retinoic acid; ATRA; CHEMS; Chol; Cholesterol; Cholesteryl hemisuccinate; DC Chol; DDAB; Dimethylaminoethane carbamoyl cholesterol; Dioctadecyl dimethyl ammonium bromide; DODAP; Folate receptor; Gene therapy; Gene transfer; Targeted delivery; Tumor

Indexed keywords

CARCINOGENS; CELL CULTURE; CELLS; DERIVATIVES; TISSUE; TUMORS; VIRUSES;

FOLATE RECEPTOR; GENE THERAPY; HUMAN MALIGNANCIES; PH-SENSITIVE LIPOSOMES;

GENES;

ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; FOLATE RECEPTOR; LIPOSOME; MEMBRANE RECEPTOR; PLASMID DNA; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER; CANCER CELL; CELL CULTURE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; MODEL; NONVIRAL GENE DELIVERY SYSTEM; OVARY CARCINOMA; PH; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SAFETY;

EID: 1942439012     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.005     Document Type: Article

References (85)

1. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New Engl. J. Med. 323:1990;570-578.
2. Friedmann T., Roblin R. Gene therapy for human genetic disease? Science. 175:1972;949-955.
3. Yao S.N., Wilson J.M., Nabel E.G., Kurachi S., Hachiya H.L., Kurachi K. Expression of human factor IX in rat capillary endothelial cells:toward somantic gene theraphy for hemophilia B. Proc. Natl. Acad. U.S.A. 88:1991;8101-8105.
4. Engelhardt J.F., Yang Y., Stratford-Perricaudet L.D., Allen E.D., Kozarsky K., Perricaudet M., Yankaskas J.R., Wilson J.M. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nature Gene. 4:1993;27-34.
5. Cristiano R.J., Smith L.C., Woo S.L. Hepatic gene theraphy:adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc. Natl. Acad. Sci. 90:1993;2122-2126.
6. Curiel D.T., Gerritsen W.R., Krul M.R. Progress in cancer gene therapy. Cancer Genet. Ther. 7:2000;1197-1199.
7. Walther W., Stein U. Therapeutic genes for cancer gene therapy. Mol. Biotechnol. 13:1999;21-28.
8. Hoffman M. New vector delivers genes to lung cells. Science. 252:1991;374.
9. Flotte T.R, Solow R., Owens R.A., Afione S., Zeitlin P.L., Carter B.J. Gene expression from adeno-associated virus vectors in airway ephithelial cells. Am. J. Respir. Cell. Mol. Biol. 7:1992;349-356.
10. Dachs G.U., Doughterty G.J., Stratford I.J., Stratford D.J., Chaplin D.J. Targeting gene therapy to cancer: a review. Oncol. Res. 9:1997;313-325.
11. Meyer F., Finer M. Gene therapy: progress and challenges. Cell. Mol. Biol. 47:2001;1277-1294.
12. Han J., Lim M., Yeom Y.I. Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine complexes. Biol. Pharm. 8:1999;836-840.
13. Hildebrandt I.J., Iyer M., Wagner E., Gambhir S.S. Optical imaging of transferring targeted PEI/DNA complexes in living subjects. Gene Ther. 10:2003;758-764.
14. Kunath K., Harpe A., Fischer D., Kissel T. Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J. Control. Release. 88:2003;159-172.
15. Liu F., Huang L. Development of non-viral vectors for systemic gene delivery. J. Control. Release. 78:2002;259-266.
16. Elwood P.C. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J. Biol. Chem. 264:1989;14893-14901.
17. Ratnam M., Marquardt H., Duhring J.L., Freisheim J.H. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry. 28:1989;8249-8254.
18. Wu M., Gunning W., Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8:1999;775-782.
19. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
20. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 85:1999;348-357.
21. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
22. Christensen E.I., Birn H., Verroust P., Moestrup S.K. Membrane receptors for endocytosis in the renal proximal tubule. Int. Rev. Cytol. 180:1998;237-284.
23. Brzezinska A., Winska P., Balinska M. Cellular aspects of folate and antifolate membrane transport. Acta Biochim. Pol. 47:2000;735-749.
24. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr. 19:1999;91-122.
25. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R. Jr., Kamen B.A. Distribution of the folate receptor gp38 in normal and malignant-cell lines and tissues. Cancer Res. 52:1992;3396-3401.
26. van Zanten-Przybysz I., Molthoff C., Gebbinck J.K., von Mensdorff-Pouilly S. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv-18 in ovarian cancer patients: a pilot study. J. Cancer Res. Clin. Oncol. 128:2002;484-492.
27. Buijs W.C., Tibben J.G., Boerman O.C., Molthoff C.F. Dosimetric analysis of chimeric monoclonal antibody MOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur. J. Nucl. Med. 25:1998;1552-1561.
28. Molthoff C.F., Prinssen H.M., Kenemans P., van Hof A.C., den Hollander W., Verheijen R.H. Escalating protein doses of chimeric monoclonal antibody MOv18 immunogolubulin G in ovarian carcinoma patients: a phase I study. Cancer. 80:1997;2712-2720.
29. van zanten-Przybysz I., Molthoff C.F., Roos J.C., Plaizier M.A., Visser G.W., Pijpers R., Kenemans P., Verheijen R.H. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv-18 in patients with ovarian cancer. J. Nucl. Med. 7:2000;1168-1176.
30. Tibben J.G., Boerman O.C., Massuger L.F., Schijf C.P., Claessens R.A., Corstens F.H. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int. J. Cancer. 66:1996;477-483.
31. Boerman O.C., Tibben J.G., Massuger L.F., Claessens R.A., Corstens F.H. Tumor targeting of the anti-ovarian carcinoma×anti-CD3/TCR bispecific monoclonal OV/TR and its parental MOv18 antibody in experimental ovarian cancer. Anticancer Res. 15:1995;2164-2174.
32. Wang S., Lee R.J., Mathias C.J., Green M.A., Low P.S. Synthesis purification, and tumor cell uptake of 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug. Chem. 7:1996;56-62.
33. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39:1998;1579-1585.
34. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40:1999;1563-1569.
35. Steinberg G., Borch R.F. Synthsis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate-targeted alkylating agents. J. Med. Chem. 44:2001;69-73.
36. Aronov O., Horowitz A.T., Gabizon A., Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs: synthesis and in vitro studies. Bioconjug. Chem. 14:2003;563-574.
37. Liu J., Kolar T.A., Lawson T.A., Gmeiner W.H. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J. Org. Chem. 66:2001;5655-5663.
38. Citro G., Szczylik C., Ginobbi P., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer. 69:1994;463-467.
39. Lu J.Y., Lowe D.A., Kennedy M.D., Low P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Target. 7:1999;43-53.
40. Kranz D.M., Patrick T.A., Brigle K.E., Spinella M.J., Roy E.J. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor-cells for lysis. Proc. Natl. Acad. Sci. USA. 92:1995;9057-9061.
41. Konda S.D., Aref M., Brechbiel M., Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate-receptor. Invest. Radiol. 35:2000;50-57.
42. Oyewumi M.O., Mumper R.J. Engineering tumor-targeted gadolinium hexandione nanopariticles for potential application in neutron capture therapy. Bioconjug. Chem. 13:2002;1328-1335.
43. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:2002;153-162.
44. Wang S., Low P.S. Folate-mediated targeting of antineoplastic drags, imaging agents, and nucleic acids to cancer cells. J. Control. Release. 53:1998;39-48.
45. Benns J.M., Kim S.W. Tailoring new gene delivery designs for specific targets. J. Drug Target. 8:2000;1-12.
46. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41:2000;147-162.
47. Leamon C.P., Low P.S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today. 6:2001;44.
48. Lu Y.J., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54:2002;675-693.
49. Gosselin M.A., Lee R.J. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol. Ann. Rev. 8:2002;103-131.
50. Brzezinska A., Winska P., Balinska M. Cellular aspects of folate and antifolate membrane transport. Acta Biochim. Pol. 47:2000;735-749.
51. Michael S.I., Curiel D.T. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther. 1:1994;223-232.
52. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
53. Douglas J.T., Curiel D.T. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromuscular Disord. 7:1997;284-298.
54. Reddy J.A., Clapp D.W., Low P.S. Retargeting of viral vectors to the folate receptor endocytic pathway. J. Control. Release. 74:2001;77-82.
55. Gottschalk S., Cristiano R.J., Smith L.C., Woo S.L. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther. 1:1994;185-191.
56. Mislick K.A., Baldeschwieler J.D., Kayyem J.F., Meade T.J. Transfection of folate-polylysine DNA complexes: evidence for lysosomal delivery. Bioconjug. Chem. 6:1995;512-515.
57. Leamon C.P., Weigl D., Hendren R.W. Folate copolymer-mediated transfection of cultured cells. Bioconjug. Chem. 10:1999;947-957.
58. Ward C.M., Pechar M., Oupicky D., Ulbrich K., Seymour L.W. Modification of PLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J. Gene Med. 4:2002;536-547.
59. van Steenis J.H., van Maarseveen E.M., Verbaan F.J., Verrijk R., Crommelin D.J.A., Storm G., Hennink W.E. Preparation and characterization of folate-targeted PEG-coated pDMAEMA-based polyplexes. J. Control. Release. 87:2003;167-176.
60. Guo W., Lee R.J. Efficient gene delivery via non-covalent complexes of folic acid and polyethylenimine. J. Control. Release. 77:2001;131-138.
61. Guo W.J., Lee R.J. Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS Pharmsci. 1:1999;E19.
62. Benns J.M., Kim S.W. Tailoring new gene delivery designs for specific targets. J. Drug Target. 8:2000;1-12.
63. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
64. Rando R.R. Regulation of protein kinase C activity by lipids. FASEB J. 2:1988;2348-2355.
65. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release. 74:2001;115-128.
66. Hofland H.E.J., Masson C., Iginla S., Osetinsky I., Reddy J.A., Leamon C.P., Scherman D., Bessodes M., Wils P. Folate-targeted gene transfer in vivo. Mol. Ther. 5:2002;739-744.
67. Dauty E., Remy J.S., Zuber G., Behr J.P. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug. Chem. 13:2002;831-839.
68. Whitmore M., Li S., Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6:1999;1867-1875.
69. Rolland A.P. From genes to gene medicines: recent advances in nonviral gene delivery. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;143-198.
70. Nishikawa M., Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 12:2001;861-870.
71. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., Leamon C.P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9:2002;1542-1550.
72. Lee R.J., Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. 271:1996;8481-8487.
73. Gosselin M.A., Guo W., Lee R.J. Incorporation of reversibly cross-linked polyplexes into LPDII vectors for gene delivery. Bioconjug. Chem. 13:2002;1044-1053.
74. Shi G., Guo W., Stephenson S.M., Lee R.J. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J. Control. Release. 80:2002;309-319.
75. Reddy J.A., Dean D., Kennedy M.D., Low P.S. Optimization of folate-conjugated liposomal vectors for folate-receptor-mediated gene therapy. J. Pharm. Sci. 88:1999;1112-1118.
76. Wang S., Low P.S. Folate-mediated targeting of antineoplastic drags, imaging agents, and nucleic acids to cancer cells. J. Control. Release. 53:1998;39-48.
77. Leamon C.P., Cooper S.R., Hardee G.E. Folate-liposome-mediated antisense oligodeoxynucleotides targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 14:2003;738-747.
78. Guo W., Lee T., Sudimack J., Lee R.G. Receptor-specific delivery of liposomes via folate-PEG-Chol. J. Liposome Res. 10:2000;179-195.
79. Rait A.S., Kathleen K.F., Xiang L., Ulick D., Chang E.H. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol. Med. 8:2002;475-486.
80. Zhou W., Yuan X., Wilson A., Yang L., Mokotoff M., Pitt B., Song L. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug. Chem. 13:2002;1220-1225.
81. Li S., Huang L. Targeted delivery of antisense oligodeoxynucleotides by LPDII. J. Liposome Res. 7:1997;63-75.
82. Pan X.Q., Wang H., Lee R.J. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res. 20:2003;417-422.
83. Kelley K.M., Rowan B.G., Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res. 63:2003;2820-2828.
84. Wang H., Zheng X., Behm F.G., Ratnam M. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood. 96:2000;3529-3536.
85. Pan X.Q., Zheng X., Shi G., Wang H., Ratnam M., Lee R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor b-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood. 15:2002;594-602.